Literature DB >> 7965476

Optimization of gene transfer into intestinal epithelial cells using a retroviral vector.

R A Noel1, P Shukla, S J Henning.   

Abstract

Somatic gene therapy has been proposed as a method of treating various metabolic diseases and conditions associated with a deficiency in secretory proteins. The intestine, because of its accessibility, large size, rapid rate of cell turnover, and known location of stem cells, is an attractive site for retroviral gene therapy. Stem cells in the intestine are known to reside in the crypts of Lieberkühn. In this study the IEC-6 cell line, derived from rat intestinal crypt cells, was used as an in vitro model to study the feasibility and dynamics of retroviral gene transfer in intestinal cells. Using a replication-deficient retrovirus, we delivered a reporter gene, bacterial beta-galactosidase (beta-gal) into NIH-3T3 fibroblasts and IEC-6 cells. Successful transduction was measured by X-gal histochemistry. Viral titers on IEC-6 cells were lower than on NIH-3T3 cells but were within the same order of magnitude. Gene transfer increased linearly with retroviral concentration up to a 1:5 dilution of retroviral supernatant. With undiluted viral medium, gene transfer was inhibited and this effect was more pronounced with the IEC-6 cells. The negative effect of the undiluted retroviral supernatant was minimized by decreasing the harvest time from the packaging cell line. An optimal plating density 12 h prior to infection was found to be approximately 10(5) cells/6-cm dish in both cell lines. The infection rate was proportionally enhanced by the use of multiple infections. In conclusion, under ideal conditions, the IEC-6 cells were infected at similar levels of efficacy as NIH-3T3 cells.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7965476     DOI: 10.1097/00005176-199407000-00007

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  7 in total

1.  Gene and cell therapy based treatment strategies for inflammatory bowel diseases.

Authors:  Sander van der Marel; Anna Majowicz; Sander van Deventer; Harald Petry; Daniel W Hommes; Valerie Ferreira
Journal:  World J Gastrointest Pathophysiol       Date:  2011-12-15

2.  Non-polarized secretion of mouse interferon-beta from gene-transferred human intestinal Caco-2 cells.

Authors:  K Kawabata; M Kondo; Y Watanabe; Y Takakura; M Hashida
Journal:  Pharm Res       Date:  1997-04       Impact factor: 4.200

3.  Efficient gene delivery to the inflamed colon by local administration of recombinant adenoviruses with normal or modified fibre structure.

Authors:  S Wirtz; P R Galle; M F Neurath
Journal:  Gut       Date:  1999-06       Impact factor: 23.059

4.  Effective in vivo and ex vivo gene transfer to intestinal mucosa by VSV-G-pseudotyped lentiviral vectors.

Authors:  Hiroshi Matsumoto; Takahiro Kimura; Kazunori Haga; Noriyuki Kasahara; Peter Anton; Ian McGowan
Journal:  BMC Gastroenterol       Date:  2010-05-11       Impact factor: 3.067

Review 5.  Targeting the gastrointestinal tract with viral vectors: state of the art and possible applications in research and therapy.

Authors:  Roeland Buckinx; Jean-Pierre Timmermans
Journal:  Histochem Cell Biol       Date:  2016-09-24       Impact factor: 2.531

Review 6.  Ex vivo gene transfer in the years to come.

Authors:  Thomas Pap; Renate E Gay; Ulf Müller-Ladner; Steffen Gay
Journal:  Arthritis Res       Date:  2001-10-09

Review 7.  Inflammatory bowel disease: Therapeutic limitations and prospective of the stem cell therapy.

Authors:  Rangnath Mishra; Punita Dhawan; Anand S Srivastava; Amar B Singh
Journal:  World J Stem Cells       Date:  2020-10-26       Impact factor: 5.326

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.